The global clinical biomarkers market is expected to reach a market size of USD 38.79 Billion by 2027 and register a robust double-digit CAGR over the forecast period, according to the latest report by Emergen Research. Increased investment in R&D projects to create more effective biomarkers, growing demand for personalized medicine globally, and an increase in the prevalence of cancer, cardiovascular diseases, and other diseases are all expected to propel the global biomarker market’s expansion over the coming years. Risk assessment, genetic testing, virus detection, DNA fingerprinting, and other biological applications all use biomarkers. When there is a rising need for a more affordable and effective dose of medication, biomarkers enable pharmaceutical companies to assess and identify novel treatments. To generate samples and build tests to decrease uncertainty in the development and production of novel therapeutics, biomarkers are used to verify and evaluate medications.
Recent developments in biomarkers, such as biomarker signatures, are improving the treatment of neurological illnesses. Early diagnosis, quicker drug development, and non-invasive testing have all been made possible as a result. New biomarkers are being discovered as a result of R&D. For instance, vitronectin is a promising biomarker for heart failure diagnosis, according to the Nature Journal in 2020. As with sTNFR2, a unique biomarker for the diagnosis of acute adult T-cell leukemia/lymphoma was identified in 2020. Due to such discoveries and technical breakthroughs, the market is predicted to grow profitably throughout the forecast period.
Some Key Highlights from the Report :
Due to increased public awareness of the importance of regular health screenings, a decline in drug attrition rates, and an increase in the population who are at a higher risk of contracting diseases like cancer, cardiovascular disease, and kidney disorders, the safety biomarkers segment held the largest market share of more than CAGR of 10.6% in 2020. Preclinical safety review and drug development take less time and money when safety biomarkers are used in preclinical trials to help identify drug candidates that are likely to be well-tolerated by humans.
Due to increased attention being paid to finding cardiac biomarkers to better understand the pathophysiology of these disorders, the cardiovascular disease segment is anticipated to grow at a CAGR of 10.4% over the estimated period. The clinical biomarkers market was dominated by the drug discovery and development segment in terms of revenue in 2019. Among the other application segments in the North American market in 2019, this sector held the dominant share of 38.2%.
With a revenue share of 39.9% in the worldwide clinical biomarkers market in 2019, North America led other regional markets. This can be linked to the increased frequency of chronic diseases and illnesses, ambitious legislative initiatives, regional regulatory authority involvement, and participation of important industry participants.
Key participants include Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Siemens Healthcare Private Limited, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Qiagen, Abbott Laboratories, Epigenomics AG, and Meso Scale Diagnostics LLC.
For this report, Emergen Research has segmented the global clinical biomarkers market based on type, disease, application, and region:
Type Outlook (Revenue, USD Billion; 2017–2027)
Disease Outlook (Revenue, USD Billion; 2017–2027)
- Cardiovascular Diseases
- Neurological Diseases
- Immunological Diseases
Application Outlook (Revenue, USD Billion; 2017–2027)
- Drug Discovery & Development
- Personalized Medicines
Regional Outlook (Revenue, USD Billion; 2017–2027)
- North America
- the U.S.
- the UK
- Rest of Europe
- the Asia Pacific
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Saudi Arabia
- Rest of MEA
To get leading market solutions, Visit the Link